Metsera, Inc.
metsera.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 12, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Nov 12, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops injectable and oral peptide medicines for people with obesity, overweight and related conditions.
10-K for FY2024, filed Mar 26, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 26, 2025
How Were They Changing?
-
Nov 13, 2025
Metsera's acquisition closed; shareholders received cash and contingent value rights
Each common share converted into $65.60 in cash plus one contingent value right tied to specified milestones.
Sources
8-K, filed Nov 13, 2025
On the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”)…View ↗
-
Nov 10, 2025
Pfizer and Metsera revised their merger agreement
Pfizer increased cash consideration to $65.60 per share and reduced the maximum contingent value payment to $20.65.
Sources
8-K, filed Nov 10, 2025
increase the upfront cash consideration to be paid by Parent for each share of the Company’s issued and outstanding common stock, par value…View ↗
-
Nov 4, 2025
Metsera's board deemed Novo Nordisk's revised bid superior
Novo Nordisk proposed an initial cash payment and dividend of $62.20 per share, plus a contingent value right of up to $24.00.
Sources
8-K, filed Nov 4, 2025
Novo Nordisk’s Proposal is structured in two steps. In the first step, immediately following the signing of a definitive agreement, Novo…View ↗
Who Did They Compete With?
Competes with Novo Nordisk, Eli Lilly, Amgen, AstraZeneca, Boehringer Ingelheim, Merck, QL Biopharma, Roche, Structure Therapeutics, Viking Therapeutics, and Zealand Pharma
10-K for FY2024, filed Mar 26, 2025The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense…View ↗
Loading...
